SPA
STRO icon

Sherbrooke Park Advisers’s Sutro Biopharma STRO Stock Holding History

Sherbrooke Park Advisers’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,051
Closed -$6.84K – 772
2025
Q1 		$6.84K Sell
1,051
-2,313
-69% -$36.4K ﹤0.01% 564
2024
Q4 		$61.9K Sell
3,364
-9,521
-74% -$291K 0.02% 701
2024
Q3 		$446K Buy
12,885
+10,978
+576% +$430K 0.1% 356
2024
Q2 		$55.9K Buy
+1,907
New +$75.4K 0.01% 860

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Sherbrooke Park Advisers's STRO Position: Q2 2025 in Review

Sherbrooke Park Advisers sold out of Sutro Biopharma (STRO) in Q2 2025, closing a stake of 1,051 shares — an estimated $6.84K sold.

Sherbrooke Park Advisers first reported a position in STRO in Q2 2024 and held it in 4 quarters. The position peaked at $446K in Q3 2024. 99 funds tracked by Wall St. Rank hold STRO as of Q2 2025.

  • Sherbrooke Park Advisers reported no remaining Sutro Biopharma position as of Q2 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 1,051 Sutro Biopharma shares in Q2 2025, an estimated $6.84K.
  • Sherbrooke Park Advisers first reported a position in Sutro Biopharma in Q2 2024 and held it in 4 quarters.
  • Sherbrooke Park Advisers's Sutro Biopharma position peaked at $446K in Q3 2024.
  • 99 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.